Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden

Trial Details

NCT ID
NCT05093231
Phase
PHASE2
Sponsor
Cambridge University Hospitals NHS Foundation Trust
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Pembrolizumab
  • Olaparib
Locations (sample)
  • Melbourne, Australia|-37.814,144.96332
  • Richmond, Australia|-37.81819,145.00176
  • Cambridge, Cambridgeshire, United Kingdom|52.2,0.11667
  • Bodelwyddan, United Kingdom|53.26827,-3.50078
  • Cardiff, United Kingdom|51.48,-3.18

Key Eligibility Criteria

  • Aged ≥ 18 years old
  • Written informed consent
  • Histologically or cytologically confirmed PDA
  • Confirmation that the PDA has TMB \>4 mutations/Mb, or dMMR gene mutation, or MSI-H by IHC. TMB status and dMMR can be obtained from either tissue,…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →